SUNITINIB SUN sunitinib (as malate) 12.5 mg capsule bottle

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

sunitinib malate, Quantity: 16.706 mg (Equivalent: sunitinib, Qty 12.5 mg)

Dostępny od:

Sun Pharma ANZ Pty Ltd

Forma farmaceutyczna:

Capsule, hard

Skład:

Excipient Ingredients: Gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; propylene glycol; butan-1-ol; isopropyl alcohol; Shellac; ethanol absolute; ammonia; potassium hydroxide

Droga podania:

Oral

Sztuk w opakowaniu:

28 capsules

Typ recepty:

(S4) Prescription Only Medicine

Wskazania:

SUNITINIB SUN is indicated for:,? treatment of advanced renal cell carcinoma (RCC),? treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic NET).

Podsumowanie produktu:

Visual Identification: Hard gelatin Size 4 capsule with opaque reddish brown cap and opaque reddish brown body, self-lock capsule, imprinted with white ink RM53 on the cap & body; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status autoryzacji:

Registered

Data autoryzacji:

2021-02-22